Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

foritinib (SAF-189)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Fosun Pharma

Drug class:

ALK inhibitor, ROS1 inhibitor

Related drugs:

‹

›

ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	SAF-189 Sensitive: C2 – Inclusion Criteria SAF-189 Sensitive : C2	SAF-189 Sensitive: C2 – Inclusion Criteria SAF-189 Sensitive : C2
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	SAF-189 Sensitive: C3 – Early Trials SAF-189 Sensitive : C3	SAF-189 Sensitive: C3 – Early Trials SAF-189 Sensitive : C3
ALK fusion + ALK G1202R	Non Small Cell Lung Cancer	ALK fusion + ALK G1202R	Non Small Cell Lung Cancer	SAF-189 Resistant: C3 – Early Trials SAF-189 Resistant : C3	SAF-189 Resistant: C3 – Early Trials SAF-189 Resistant : C3
ALK fusion + ALK I1179T	Non Small Cell Lung Cancer	ALK fusion + ALK I1179T	Non Small Cell Lung Cancer	SAF-189 Resistant: C3 – Early Trials SAF-189 Resistant : C3	SAF-189 Resistant: C3 – Early Trials SAF-189 Resistant : C3
ALK fusion + FAT3 mutation	Non Small Cell Lung Cancer	ALK fusion + FAT3 mutation	Non Small Cell Lung Cancer	SAF-189 Resistant: C3 – Early Trials SAF-189 Resistant : C3	SAF-189 Resistant: C3 – Early Trials SAF-189 Resistant : C3
ALK fusion + FAT4 mutation	Non Small Cell Lung Cancer	ALK fusion + FAT4 mutation	Non Small Cell Lung Cancer	SAF-189 Resistant: C3 – Early Trials SAF-189 Resistant : C3	SAF-189 Resistant: C3 – Early Trials SAF-189 Resistant : C3
SDK1-ALK fusion	Lung Adenocarcinoma	SDK1-ALK fusion	Lung Adenocarcinoma	SAF-189 Sensitive: C4 – Case Studies SAF-189 Sensitive : C4	SAF-189 Sensitive: C4 – Case Studies SAF-189 Sensitive : C4